Table 1.
Baseline patient characteristics
| Characteristic | Imatinib arm (%), n=41 |
Placebo arm (%), n=40 |
|---|---|---|
| Median age, years (IQR) | 57 (52–65) | 61 (54–67) |
| Male gender | 29 (71) | 26 (65) |
| ECOG performance status | ||
| 0–1 | 28 (68) | 28 (70) |
| 2–3 | 13 (32) | 12 (30) |
| Primary site | ||
| Stomach | 16 (39) | 13 (33) |
| Small bowel | 20 (49) | 25 (62) |
| Others | 5 (12) | 2 (5) |
| Previous third or more lines of therapy | 16 (39) | 16 (40) |
| Prior nilotinib | 7 (17) | 9 (22) |
| Prior regorafenib or sorafenib | 5 (12) | 10 (25) |
| Prior dovitinib | 7 (17) | 3 (8) |
| Duration of previous first-line imatinibtherapy (400 mg/day) | ||
| ≥6 and <12 months | 3 (7) | 5 (13) |
| ≥12 and <24 months | 14 (34) | 10 (25) |
| ≥24 months | 24 (59) | 25 (62) |
| Duration of previous second-line sunitinib | ||
| ≥6 months | 26 (63) | 18 (45) |
| Primary genotype | N=38 | N=39 |
| KIT exon 11 mutation | 31 (82) | 30 (77) |
| KIT exon 9 mutation | 4 (10) | 5 (13) |
| Others | 3 (8) | 4 (10) |
ECOG, Eastern Cooperative Oncology Group